Screener
Axsome Therapeutics AXSM Debt-to-equity
Debt-to-equity at other companies
Other financials
Where this comes from
Calculated from Axsome Therapeutics’s reported figures.
Based on the most recent quarter.
The source filing: Axsome Therapeutics’s 10-Q, filed May 4, 2026. Open the filing →
- Filed
- May 4, 2026, 5:04 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-204274
FAQ
- What is Axsome Therapeutics's debt-to-equity?
- Axsome Therapeutics (AXSM) reported debt-to-equity of 4× in Q1 2026.
- How has Axsome Therapeutics's debt-to-equity changed year-over-year?
- Axsome Therapeutics's debt-to-equity increased by 1.5% year-over-year, from 4× to 4×.
- What is the long-term trend for Axsome Therapeutics's debt-to-equity?
- Over 5 years (2020 to 2025), Axsome Therapeutics's debt-to-equity has grown at a 41.2% compound annual growth rate (CAGR), from 0.4× to 2.5×.
- What does debt-to-equity mean?
- Total debt (including capitalized leases and financing obligations) divided by shareholders' equity at the quarter end. Measures how much the company is financed by debt relative to equity.
Ask your AI about Axsome Therapeutics's debt-to-equity.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude